Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in obese adolescents: A looming marker of cardiac dysfunction

Hepatology

Volumn 59, Issue 2, 2014, Pages 372-374

  Santoro, Nicola ^a   Caprio, Sonia ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; CHILDHOOD OBESITY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE MARKER; EDITORIAL; HEART DISEASE; HEART HYPERTROPHY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOTOXICITY; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84893679656     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26663     Document Type: Editorial

References (19)

1. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496-500.
2. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unraveling the mechanism. Lancet 2010;375:2267-2277.
3. Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006;91:4287-4294.
4. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009;49:1896-1903.
5. D'Adamo E, Northrup V, Weiss R, Santoro N, Pierpont B, Savoye M, et al. Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr 2010;92:500-508.
6. D'Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, et al Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 2010;33:1817-1822.
7. Cali AM, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Otvos JD, et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents. Diabetes Care 2007;30:3093-3098.
8. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008;118:277-283.
9. Perseghin G, Natali G, De Cobelli F, Lattuada G, Esposito A, Belloni E, et al. Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care 2007;30:1520-1526.
10. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014;59:461-470.
11. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
12. Santoro N, D'Adamo E, Kursawe K, Dykas D, Cali A, Bale AE, et al. A common variant in the patatin-like phopholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010;52:1281-1290
13. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, et al. A variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2011;55:781-789.
14. Vos M, McClain CJ. Nutrition and nonalcoholic fatty liver disease in children. Curr Diab Rep 2008;10:399-406.
15. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
16. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E: Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-437.
17. Giannini C, Feldstein A, Santoro N, Kim G, Kursawe R, Pierpont B, Caprio S. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 2013;98:2993-3000.
18. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013;4:2019.
19. Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8:e67160.